These tech giants have seen their stock prices climb based on momentum in AI spending. Analysts see potential for slowing revenue growth for both companies, which could cause the market to reprice the stocks.
Source: https://www.fool.com/investing/2025/12/26/popular-stocks-sel…
Eli Lilly is at the forefront of the GLP-1 weight loss drug market. The company’s leading position is already being tested by Novo Nordisk’s GLP-1 weight loss pill.
The tech sector is hot, but the next decade may be about power. Oklo and NuScale are designing small nuclear reactors.
At least for now, concerns about a key partner have derailed Oracle’s growth story. Figma may finally be recovering from its post-IPO slump.
